Geulah Livshits
Stock Analyst at Chardan Capital
(4.37)
# 336
Out of 5,157 analysts
253
Total ratings
47.24%
Success rate
20.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintains: Buy | $3.5 | $2.64 | +32.58% | 11 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $26 → $27 | $13.47 | +100.45% | 19 | Mar 2, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $174 → $210 | $142.11 | +47.77% | 7 | Feb 24, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $220 → $323 | $261.08 | +23.72% | 15 | Feb 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $74 → $76 | $52.80 | +43.94% | 17 | Feb 17, 2026 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $17 | $7.20 | +136.11% | 14 | Jan 13, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $12 | $4.57 | +162.58% | 17 | Jan 6, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $26 | $8.87 | +193.12% | 14 | Dec 18, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 → $8 | $0.90 | +793.85% | 14 | Dec 12, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 → $13 | $0.99 | +1,208.77% | 11 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 | $10.50 | +138.10% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $5.62 | +255.87% | 15 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $21 | $8.51 | +146.77% | 6 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $4.05 | +122.22% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $5.20 | +226.92% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $8.18 | +83.37% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $5.30 | +107.55% | 22 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.76 | +525.00% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.77 | +116.61% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.76 | +428.35% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.32 | +261.45% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $54.98 | +278.32% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.69 | +2,229.64% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $9.90 | +809.09% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $5.00 | -20.00% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $21.86 | -17.66% | 1 | Oct 27, 2020 |
Editas Medicine
Mar 9, 2026
Maintains: Buy
Price Target: $3.5
Current: $2.64
Upside: +32.58%
Intellia Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $26 → $27
Current: $13.47
Upside: +100.45%
Palvella Therapeutics
Feb 24, 2026
Maintains: Buy
Price Target: $174 → $210
Current: $142.11
Upside: +47.77%
Krystal Biotech
Feb 18, 2026
Maintains: Buy
Price Target: $220 → $323
Current: $261.08
Upside: +23.72%
CRISPR Therapeutics AG
Feb 17, 2026
Maintains: Buy
Price Target: $74 → $76
Current: $52.80
Upside: +43.94%
Lexeo Therapeutics
Jan 13, 2026
Maintains: Buy
Price Target: $17
Current: $7.20
Upside: +136.11%
Taysha Gene Therapies
Jan 6, 2026
Maintains: Buy
Price Target: $12
Current: $4.57
Upside: +162.58%
4D Molecular Therapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $26
Current: $8.87
Upside: +193.12%
Tenaya Therapeutics
Dec 12, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $0.90
Upside: +793.85%
Senti Biosciences
Dec 9, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $0.99
Upside: +1,208.77%
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $10.50
Upside: +138.10%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $5.62
Upside: +255.87%
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $8.51
Upside: +146.77%
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.05
Upside: +122.22%
Nov 6, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $5.20
Upside: +226.92%
Nov 4, 2025
Maintains: Buy
Price Target: $15
Current: $8.18
Upside: +83.37%
Oct 14, 2025
Maintains: Buy
Price Target: $11
Current: $5.30
Upside: +107.55%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.76
Upside: +525.00%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.77
Upside: +116.61%
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.76
Upside: +428.35%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $3.32
Upside: +261.45%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $54.98
Upside: +278.32%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.69
Upside: +2,229.64%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $9.90
Upside: +809.09%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $5.00
Upside: -20.00%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $21.86
Upside: -17.66%